This review summarizes the epidemiology, clinical course, and diagnosis of malaria. The influence of infection during pregnancy upon maternal and neonatal anemia, stillbirth, preterm labor, low birth weight, and congenital malaria is discussed. Options for treatment and prophylaxis during pregnancy are presented. Infect.
PATHOGENESIS
Malaria is caused by the genus Plasmodium. There are four species which infect man: P. falciparum, P. vivax, P. ovale, and P. malariae, z The infection is transmitted through the Anopheles mosquito. The life cycle is complex with both sexual and asexual reproduction (Fig. 1) . The Dyserythropoiesis is yet another potential contributor to the anemia observed in infected patients. This abnormal bone marrow response to anemia has been observed in children 11 and includes erythroblast multinuclearity, karyorrhexis, incomplete and unequal amitotic nuclear division, and cytoplasmic bridging.
In addition to maternal anemia, malaria is also associated with fetal anemia. 
Preterm Labor
There is currently little data demonstrating a causal relationship between malaria and preterm labor. Studies from sub-Saharan Africa are often limited by imprecise estimates of gestational age.
Low Birth Weight
The prevalence of low birth weight (<2,500 g) infants in malaria-endemic areas ranges from 15 to 30%. 17, 18 Diverse factors are associated with the delivery of these small infants including environmental and demographic characteristics. Several studies have demonstrated that the prevalence of low birth weight infants is higher among primigravidas than multigravidas. 17, 19 Maternal complications of Plasmodium infection such as anemia are also associated with low birth weight. Both the multifactorial nature of the problem and difficulty in accurate assessment of gestational age make determination of the direct effect of malaria on birth weight elusive.
Contributions to abnormal growth by circulating malaria parasites, malaria-associated placental lesions, and maternal anemia were evaluated by Meuris and colleagues. 17 The prevalence of low birth weight was 15% in the total population; however, in women without these factors, only 6.4% of infants had low birth weight. When both circulating parasites and placental lesions were found at birth, the percentage of low birth weight was 25 Infections caused by P. vivax, P. ovale, and P. malariae should be treated with chloroquine. P. vivax and P. ovale both have dormant forms, referred to as hypnozoites, which are asymptomatic. These forms are not susceptible to chloroquine and, therefore, in non-pregnant individuals a course of primaquine is added at the completion of the initial therapy. Prior to treatment with primaquine, individuals at risk for glucose-6-phosphate deficiency should be evaluated. Those patients with <10% residual enzyme activity should not be treated due to the risk of hemolytic disease.
Primaquine can cause hemolytic disease in the fetus, so it is not recommended in pregnancy. Rather, the gravida should be maintained on prophylactic doses of chloroquine until delivery in an effort to prevent relapse during gestation. She can then be treated with primaquine in the postpartum period, e When infection is caused by P. falciparum, it is important to know if the infection was acquired in an area with reported chloroquine resistance. If the infection was acquired in an area without reported resistance, treatment with oral chloroquine is adequate. For infections thought to be caused by re- 
Prophylaxis
Because prophylactic treatment can fail, it should be emphasized that the optimal method for preventing malarial infection in the non-immune gravida is to refrain from travel to malaria-endemic regions. When such travel is unavoidable, however, there are several prophylactic regimens safe for use in pregnancy ( Table 2 ). The cost-effectiveness of these regimens for women living in endemic regions remains to be proven.
Mefloquine has been evaluated as prophylaxis for chloroquine-resistant malaria. 3 In a doubleblind, placebo-controlled study in Thailand, mefloquine gave >86% protection against P. falciparum and complete protection against P. vivax In Malawi, another area with chloroquineresistant malaria, prophylaxis was evaluated in primi-and secundagravidas.
3e Three regimens were compared: chloroquine treatment followed by chloroquine prophylaxis (CQ/CQ), sulfadoxine/ pyrimethamine treatment followed by chloroquine prophylaxis (SP/CQ), and sulfadoxine/ pyrimethamine treatment and prophylaxis (SP/SP). Combined treatment and prophylaxis with sulfadoxine/pyrimethamine resulted in a marked decrease in maternal parasitemia (32% for CQ/CQ and 14% for SP/CQ vs 3% for SP/SP). Placental parasitemia was also significantly reduced (32%, 25%, and 9%, respectively, for CQ/CQ, SP/CQ, and SP/SP). Three percent of SP-treated infants developed scleral icterus; all cases resolved without complications after phototherapy.
The effect of proguanil, either alone or in combination with chloroquine, was evaluated by Mutabingwa et al. 3 Therapy was noted to reduce the rate of low birth weight infants, however, due to the small numbers of participants, the differences were not significant. 3 Placental parasitemia was significantly reduced. In primigravidas, the prevalence of severe anemia was also reduced.
SUMMARY
Malaria is caused by four species of P/asmodium. 
